Environmental, Social And Governance Report

Overview

The report is ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s first ESG Report, covering its consolidated entities and Shanghai operations for 2023. It describes Board-led ESG oversight supported by an ESG Working Group and materiality-based topic prioritization. The statistical table reports 145 employees, 1,639.62 tonnes of total Scope 1 and Scope 2 GHG emissions, and 2,342.04 kWh in '000s of total energy consumption. The report also details initiatives covering compliance, responsible sourcing, employee empowerment, health and safety, and healthcare accessibility.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2023
Period: 1 January 2023 – 31 December 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services